By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan" report to their offering. The market for biosimilars is expected be around 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Dr. Smith previously held the positions of Chief Intellectual Property Counsel for Alpharma, Inc. and before that Head of North American Intellectual Proper
Generic Pharmaceutical Association issued the following statement by Ralph G. Neas:. "The Health Affairs blog entry of October 21st entitled" The $500 Billion Medicare Slowdown: A Story About Part D, "confirms the central role that generic drugs have played in lowering healthcare costs in Medicare. This new analysis follows a recent report by the
?Diluted EPS, excluding specified items, was $0.62 in the third quarter, representing growth of 12.7 percent, and above the previous guidance range of $0.59 to $0.61. See page 2 for additional information on how results from the developed markets branded generics pharmaceuticals business are being reported.? Abbott is raising the mid-point of i
Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications for generic versions of Actavis' Lo Loestrin Fe.
The focus of the Bioequivalence Conference is to help bridge the gap between the scientific community and regulatory agencies in order to safely bring a new drug to market. Oksana Olkhovyk will be presenting a poster session titled "Understanding the Power of Chemically-specific Analysis for Formulation Development and Establishing Bioequivalence i
Parliamentary Secretary for National Health Services, Regulations and Coordination Dr Darshan Wednesday informed the National Assembly that the government was promoting sale of effective and quality generic drugs at affordable prices to the patients. Replying during Question Hour in the House, Dr Darshan said that after the promulgation of Drug...
IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, announced its financial results for the third quarter ended September 30, 2014. Total revenues of $6.7 million in the third quarter of 2014, an increase of 67% over the same quarter in 2013 Total revenues of $20.0 million for the nine months ended September 30, 2
IGI Laboratories recently appointed Steven Koehler to its Board of Directors. According to a release from the company, Koehler retired from Merck& Co in September of 2011, where he served as Vice President, Schering-Plough Controller and Special Projects. IGI Laboratories is a specialty generic drug development and manufacturing company.
Ming Yeung talks to a few experts in the field to find out whether these drugs are as safe as they are affordable. President of the Society of Hospital Pharmacists of Hong Kong, William Chui Chun-ming, argued that savings on healthcare in Hong Kong could tally to HK $230 million a year from now until 2022- if public health authorities introduced mo
Generic Pharmaceutical Association issued the following statement by Ralph G. Neas, President and CEO, GPhA:. Over the past 30 years, generic utilization in the United States increased from just 20% in the mid-1980s to 86% today. According to the IMS Institute for Healthcare Informatics, in the past decade generic drugs have saved the U.S. health c
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today updates that its Qionglai Facility Good Manufacturing Practice certification by the China Food& Drug Administration's is on schedule.
ABBOTT PARK, Illinois, Oct. 22, 2014/ PRNewswire/ Abbott today announced financial results for the third quarter ended Sept. 30, 2014. See page 2 for additional information on how results from the developed markets branded generics pharmaceuticals business are being reported. Abbott is raising the mid-point of its full-year 2014 adjusted EPS guid
DUBLIN and BOSTON, Oct. 22, 2014/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health, Inc., which is developing relamorelin, a peptide ghrelin agonist, for t
The Association of Southeast Asian Nations issued the following secretariat news:. A two-day workshop for representatives of Pharmaceutical Product Working Group or the National Drug Regulatory Authorities from ASEAN Member States was held on 20-21 October in Jakarta, Indonesia. The ASEAN Consultative Committee on Standards and Quality PPWG, in...
Oct. 22 Cecil- based generic drug giant Mylan Inc. said in a government filing today that it still plans to complete its deal to buy a chunk of Abbott Laboratories' overseas generics business in the first quarter next year and reincorporate in the Netherlands, but the two companies have slightly adjusted the terms of the transaction. Under the ne
A legal framework to approve biosimilars was established in Europe in 2003, and they have been used safely since the first medication was approved in 2006. However, four years after the passage of PPACA, not a single biosimilar has been approved by the FDA. CAGW's poll shows that 78 percent of voters agree that healthcare costs are out of control a
CANDA NK-2, LLC, a subsidiary of CANDA Pharma, LLC, announced today that the company has moved to dismiss a patent infringement lawsuit, based on lack of personal jurisdictions over the defendants. The claim was originally filed on Oct. 8, 2014 by Eli Lilly and Company in the United States District Court for the Southern District of Indiana. The
FDA has made the determination because of the submission of applications to the Director of the United States Patent and Trademark Office, Department of Commerce, for the extension of a patent which claims that food additive. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 and the Generic Animal Drug an
Last year, Health Partners Plans launched its new Medicare product, Health Partners Medicare, to record-breaking enthusiasm enrolling more than 1,500 members during its first Annual Enrollment Period. We are pleased to offer Philadelphia residents four Medicare Advantage plans, with options that include $0 premiums and $0 generic drugs, sa
Impax Laboratories, Inc. today announced that Carole Ben-Maimon, M.D., president of Global Pharmaceuticals, the Company's generic pharmaceutical division, has resigned for personal and family reasons. Ben-Maimon's resignation will be effective November 3, 2014. Logo- http://photos.prnewswire.com/prnh/20140402/PH96035LOGO "For more than three years,
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of its Regabatin? XR product development. The Company intends to present the following informatio
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of its Regabatin? XR product development. The Company intends to present the following informat
Southwestern Pennsylvania advocates from organizations including the Multiple Sclerosis Society, the Arthritis Foundation, and the American Cancer Society, as well as Cecil Township- based generic drug manufacturer Mylan, will discuss current regulatory and non-governmental barriers to new life-saving therapies and ways to improve the Food and Drug
Today, Analysts Review released its research reports regarding UnitedHealth Group Inc., Celgene Corporation, Actavis plc, Bristol-Myers Squibb Company and Salix Pharmaceuticals Ltd.. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7391-100free. UnitedHealth Group Inc. Research Reports On...